MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 319808 | Name: Carotegrast

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Carotegrast, also known as HCA 2969, is a metoblite of carotegrast methyl. HCA2969 selectively inhibited the in vitro binding of α4 integrin (α4β7/α4β1) to the cell adhesion molecules. Carotegrast methyl, also known as AJM300 and PTC-100, is an orally-active small molecule that antagonises the α4 integrin receptor.

Chemical Structure

Carotegrast
Carotegrast
CAS#401904-75-4

Theoretical Analysis

MedKoo Cat#: 319808

Name: Carotegrast

CAS#: 401904-75-4

Chemical Formula: C27H24Cl2N4O5

Exact Mass: 554.1124

Molecular Weight: 555.41

Elemental Analysis: C, 58.39; H, 4.36; Cl, 12.77; N, 10.09; O, 14.40

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Carotegrast; HCA 2969; HCA-2969; HCA2969;
IUPAC/Chemical Name
(S)-2-(2,6-dichlorobenzamido)-3-(4-(6-(dimethylamino)-1-methyl-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl)phenyl)propanoic acid
InChi Key
YQKBOUPIOWUMTE-NRFANRHFSA-N
InChi Code
InChI=1S/C27H24Cl2N4O5/c1-31(2)17-11-12-22-18(14-17)25(35)33(27(38)32(22)3)16-9-7-15(8-10-16)13-21(26(36)37)30-24(34)23-19(28)5-4-6-20(23)29/h4-12,14,21H,13H2,1-3H3,(H,30,34)(H,36,37)/t21-/m0/s1
SMILES Code
O=C(O)[C@@H](NC(C1=C(Cl)C=CC=C1Cl)=O)CC2=CC=C(N3C(N(C)C4=C(C=C(N(C)C)C=C4)C3=O)=O)C=C2
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 555.41 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Kobayashi T, Hibi T. Improving IBD outcomes in the era of many treatment options. Nat Rev Gastroenterol Hepatol. 2023 Feb;20(2):79-80. doi: 10.1038/s41575-022-00738-z. Erratum in: Nat Rev Gastroenterol Hepatol. 2023 Jan 30;: PMID: 36635556; PMCID: PMC9838431. 2: Kambayashi R, Goto A, Izumi-Nakaseko H, Oikawa I, Ikeda N, Matsuda K, Takei Y, Matsumoto A, Kumagai Y, Sugiyama A. Appraisal of ICH E14/S7B Q&As adopted in February 2022 using thorough QT/QTc study data for α4-integrin antagonist carotegrast methyl in Japanese healthy subjects. J Pharmacol Sci. 2022 Nov;150(3):191-199. doi: 10.1016/j.jphs.2022.08.007. Epub 2022 Sep 2. PMID: 36184124. 3: Dhillon S. Carotegrast Methyl: First Approval. Drugs. 2022 Jun;82(9):1011-1016. doi: 10.1007/s40265-022-01732-0. PMID: 35723803. 4: Matsuoka K, Watanabe M, Ohmori T, Nakajima K, Ishida T, Ishiguro Y, Kanke K, Kobayashi K, Hirai F, Watanabe K, Mizusawa H, Kishida S, Miura Y, Ohta A, Kajioka T, Hibi T; AJM300 Study Group. AJM300 (carotegrast methyl), an oral antagonist of α4-integrin, as induction therapy for patients with moderately active ulcerative colitis: a multicentre, randomised, double-blind, placebo- controlled, phase 3 study. Lancet Gastroenterol Hepatol. 2022 Jul;7(7):648-657. doi: 10.1016/S2468-1253(22)00022-X. Epub 2022 Mar 30. PMID: 35366419. 5: Gubatan J, Keyashian K, Rubin SJS, Wang J, Buckman CA, Sinha S. Anti- Integrins for the Treatment of Inflammatory Bowel Disease: Current Evidence and Perspectives. Clin Exp Gastroenterol. 2021 Aug 24;14:333-342. doi: 10.2147/CEG.S293272. PMID: 34466013; PMCID: PMC8402953. 6: Solitano V, Parigi TL, Ragaini E, Danese S. Anti-integrin drugs in clinical trials for inflammatory bowel disease (IBD): insights into promising agents. Expert Opin Investig Drugs. 2021 Oct;30(10):1037-1046. doi: 10.1080/13543784.2021.1974396. Epub 2021 Sep 6. PMID: 34449288. 7: Cheng Y, Liang X, Hao J, Niu C, Lai Y. Application of a PBPK model to elucidate the changes of systemic and liver exposures for rosuvastatin, carotegrast, and bromfenac followed by OATP inhibition in monkeys. Clin Transl Sci. 2021 Sep;14(5):1924-1934. doi: 10.1111/cts.13047. Epub 2021 May 31. PMID: 34058067; PMCID: PMC8504809. 8: Misselwitz B, Juillerat P, Sulz MC, Siegmund B, Brand S; Swiss IBDnet, an official working group of the Swiss Society of Gastroenterology. Emerging Treatment Options in Inflammatory Bowel Disease: Janus Kinases, Stem Cells, and More. Digestion. 2020;101 Suppl 1:69-82. doi: 10.1159/000507782. Epub 2020 Jun 22. PMID: 32570252. 9: Lucaciu LA, Seicean R, Seicean A. Small molecule drugs in the treatment of inflammatory bowel diseases: which one, when and why? - a systematic review. Eur J Gastroenterol Hepatol. 2020 Jun;32(6):669-677. doi: 10.1097/MEG.0000000000001730. PMID: 32282548. 10: Fukase H, Kajioka T, Oikawa I, Ikeda N, Furuie H. Food Effect on a Single High Dose of Carotegrast Methyl, an Oral Antagonist of α4-Integrin, in Healthy Male Subjects: A Randomised, Placebo-Controlled, Double-Blind Study. Clin Drug Investig. 2020 Mar;40(3):237-247. doi: 10.1007/s40261-019-00879-1. PMID: 31965548; PMCID: PMC7035301. 11: Fukase H, Kajioka T, Oikawa I, Ikeda N, Furuie H. AJM300, a novel oral antagonist of α4-integrin, sustains an increase in circulating lymphocytes: A randomised controlled trial in healthy male subjects. Br J Clin Pharmacol. 2020 Mar;86(3):591-600. doi: 10.1111/bcp.14151. Epub 2020 Jan 28. PMID: 31658381; PMCID: PMC7080631. 12: Shukla T, Sands BE. Novel Non-biologic Targets for Inflammatory Bowel Disease. Curr Gastroenterol Rep. 2019 Apr 23;21(5):22. doi: 10.1007/s11894-019-0689-2. PMID: 31016396. 13: Li H, Huang SY, Shi FH, Gu ZC, Zhang SG, Wei JF. α4β7 integrin inhibitors: a patent review. Expert Opin Ther Pat. 2018 Dec;28(12):903-917. doi: 10.1080/13543776.2018.1549227. Epub 2018 Nov 22. PMID: 30444683. 14: Pérez-Jeldres T, Tyler CJ, Boyer JD, Karuppuchamy T, Bamias G, Dulai PS, Boland BS, Sandborn WJ, Patel DR, Rivera-Nieves J. Cell Trafficking Interference in Inflammatory Bowel Disease: Therapeutic Interventions Based on Basic Pathogenesis Concepts. Inflamm Bowel Dis. 2019 Jan 10;25(2):270-282. doi: 10.1093/ibd/izy269. PMID: 30165490; PMCID: PMC6327230. 15: Park SC, Jeen YT. Anti-integrin therapy for inflammatory bowel disease. World J Gastroenterol. 2018 May 7;24(17):1868-1880. doi: 10.3748/wjg.v24.i17.1868. PMID: 29740202; PMCID: PMC5937204. 16: White JR, Phillips F, Monaghan T, Fateen W, Samuel S, Ghosh S, Moran GW. Review article: novel oral-targeted therapies in inflammatory bowel disease. Aliment Pharmacol Ther. 2018 Jun;47(12):1610-1622. doi: 10.1111/apt.14669. Epub 2018 Apr 19. PMID: 29672874. 17: Vetter M, Neurath MF. Emerging oral targeted therapies in inflammatory bowel diseases: opportunities and challenges. Therap Adv Gastroenterol. 2017 Oct;10(10):773-790. doi: 10.1177/1756283X17727388. Epub 2017 Sep 5. PMID: 29051788; PMCID: PMC5638182. 18: Coskun M, Vermeire S, Nielsen OH. Novel Targeted Therapies for Inflammatory Bowel Disease. Trends Pharmacol Sci. 2017 Feb;38(2):127-142. doi: 10.1016/j.tips.2016.10.014. Epub 2016 Dec 1. PMID: 27916280. 19: Naganuma M, Mizuno S, Nanki K, Sugimoto S, Kanai T. Recent trends and future directions for the medical treatment of ulcerative colitis. Clin J Gastroenterol. 2016 Dec;9(6):329-336. doi: 10.1007/s12328-016-0686-z. Epub 2016 Oct 3. PMID: 27699641. 20: Nielsen OH, Seidelin JB, Ainsworth M, Coskun M. Will novel oral formulations change the management of inflammatory bowel disease? Expert Opin Investig Drugs. 2016 Jun;25(6):709-18. doi: 10.1517/13543784.2016.1165204. Epub 2016 Mar 28. PMID: 26967267.